New anticoagulants that target human factor XIIIa to prevent blood clots
Official title: Inhibitors of Human Factor XIIIa as New Anticoagulants
Funded at Xavier University of Louisiana · NIH-11049086 · Data updated 2026-11-12
This study is looking to create safer blood-thinning medications that target a specific part of the blood clotting process, which could help people at risk of blood clots avoid the bleeding problems that can come with current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xavier University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | April 17, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $150,000 |
| NIH project number | 5R16GM149412-03 |
| Project ID | NIH-11049086 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for venous thromboembolism, particularly those who may have experienced complications from current anticoagulant therapies.
✕Less likely to help
Patients who do not suffer from venous thromboembolism or those who have contraindications to anticoagulant therapy may not benefit from this research.
What this research studies
This research focuses on developing safer anticoagulants that specifically inhibit human factor XIIIa, a key player in the blood coagulation process. By targeting this factor, the goal is to create treatments for venous thromboembolism (VTE) that minimize the risk of bleeding complications associated with current anticoagulants. The approach involves laboratory experiments to assess the effectiveness of these inhibitors in normal human blood, aiming to provide a safer alternative for patients at risk of blood clots.
Why it matters
Potential benefit: If successful, this research could lead to new anticoagulant therapies that effectively prevent blood clots without the significant bleeding risks of existing treatments.
How similar studies have gone: While targeting factor XIIIa is a novel approach, preliminary studies have shown promise in using this strategy to reduce bleeding risks, indicating potential for success.
Where this research is happening
-
Xavier University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Al-Horani, Rami a — Xavier University of Louisiana
- Study coordinator: Al-Horani, Rami a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.